Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia

Clearmind Medicine Inc. (Nasdaq: CMND) has published a patent application in Japan for novel compositions and methods aimed at treating dyskinesia, a neurological movement disorder. The application focuses on the use of 3-Methylmethcathinone (3-MMC) to prevent or reduce symptoms of dyskinesia, and includes claims for combinations of 3-MMC with Palmitoylethanolamide (PEA), known for its anti-inflammatory and neuroprotective properties.